Recent Updates
Recently added Catalysts
RCUS Positive Sentiment

Arcus Biosciences Announces New Employment Inducement Grants

Monday, October 26, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arcus Biosciences announced the granting of stock options to three new employees. A total of 10,650 shares were awarded at an exercise price of $18.54, reflecting the company's commitment to attracting talent. This move supports their focus on developing cancer and immune disease therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • New employment inducement grants announced.
  • Options granted for 10,650 shares.
  • Exercise price set at $18.54.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
2.8%
average across 10 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
Etrumadenant
Phase 1 · Prostatic Neoplasms, Castration-Resistant

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 10,650 shares of the Company’s common stock at an exercise price per share of $18.54, which was the closing price

Frequently Asked Questions

What did Arcus Biosciences announce?

They announced new employment inducement grants for three employees.

How many shares were granted?

A total of 10,650 shares were granted to the new employees.

What is the exercise price per share?

The exercise price per share is $18.54.

Who granted the stock options?

The Compensation Committee of the Board of Directors granted the options.

ShareAdd on Google
Tags: RCUS Arcus Biosciences stock options employment grants biopharmaceutical
Last updated: Oct 26, 2026

Biotech snapshot

Cash runway
$775M liquidity · $40M/mo burn
~17 mo
Low dilution risk
Lead asset
EtrumadenantPhase 1
Prostatic Neoplasms, Castration-Resistant →

Catalyst track record

+65%
best trade around RCUS's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for RCUS.

See every catalyst's timing & PoA →